Johnathon Liddicoat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johnathon Liddicoat has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Kathleen Liddell
Centre for Law, Medicine and Life Sciences, Faculty of Law University of Cambridge Cambridge UK
15 shared publications- Mateo Aboy
University of Cambridge
12 shared publications Cristina Crespo
Research Scholar, Centre for Law, Medicine and Life Sciences, Faculty of Law, University of Cambridge, Cambridge, UK
10 shared publications- Dianne Nicol
Faculty of Law, University of Tasmania, Hobart, Australia
8 shared publications Mateo Aboy
University of Cambridge
5 shared publications- Timo Minssen
University of Copenhagen
5 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by ScienceOpen
From Off-Label Evidence to Authorised Care: Mapping Europe’s Article 48 Drug Repurposing Pipeline
- 30 July 2026
- Published by ScienceOpen
Open AccessFrom Off-Label Evidence to Authorised Care: Mapping Europe’s Article 48 Drug Repurposing Pipeline
- Open Access
- 16 June 2026
- Published by Cambridge University Press (CUP) in The Cambridge Law Journal
- Vol. 85 (2) , 471-496
THE REPUBLIC OF TRANSLATIONAL MEDICINE
Established pharmaceutical innovation theory holds that companies and patents are essential for developing new treatments. Yet, it does not adequately explain numerous clinical trials conducted by hospitals and universities. This paper introduces a new, complementary theory that describes a parallel system of innovation, focused on new uses of already authorised drugs, particularly once generics are available. These trials are driven by incentives previously associated with “open science” and “user innovation” rather than by patents and cost 90 per cent less than commercial equivalents. This “hidden” research system could regularly provide society with affordable treatments.
- 16 June 2026
- Published by Cambridge University Press (CUP) in The Cambridge Law Journal
- Vol. 85 (2) , 471-496
Open AccessTHE REPUBLIC OF TRANSLATIONAL MEDICINE
Established pharmaceutical innovation theory holds that companies and patents are essential for developing new treatments. Yet, it does not adequately explain numerous clinical trials conducted by hospitals and universities. This paper introduces a new, complementary theory that describes a parallel system of innovation, focused on new uses of already authorised drugs, particularly once generics are available. These trials are driven by incentives previously associated with “open science” and “user innovation” rather than by patents and cost 90 per cent less than commercial equivalents. This “hidden” research system could regularly provide society with affordable treatments.
- Open Access
- 21 October 2024
- Published by Wiley in The Journal of World Intellectual Property
How many drugs are repositioned each year in Europe?
For two decades, commentators have argued for law and policy reform to incentivise organisations to develop new indications for (already) authorised drugs, an area of drug development known as ‘repositioning’. In short, they argue that hurdles in patent and pharmaceutical law hinder repositioning and, therefore, reform is required to increase its use. Yet, these arguments are made primarily on anecdotes; the empirical evidence is scant. One foundational question is how many drugs are repositioned each year in Europe. This study develops a method to examine the number authorised each year. The results show a marked increase in repositioning over the last 3 years, and that the number per year is comparable, though slightly fewer than, the number of new compounds, indicating modest to higher‐than‐expected activity. This study considers what the results mean for four suggested reform options, including the EU Commission's recent proposal. We conclude that the reforms may not achieve their goals or that further evidence is required before we can know whether they will be effective. Lastly, this paper explains how the method and data in this study could serve as a benchmark for evaluating the success of future reforms.
- 21 October 2024
- Published by Wiley in The Journal of World Intellectual Property
Open AccessHow many drugs are repositioned each year in Europe?
For two decades, commentators have argued for law and policy reform to incentivise organisations to develop new indications for (already) authorised drugs, an area of drug development known as ‘repositioning’. In short, they argue that hurdles in patent and pharmaceutical law hinder repositioning and, therefore, reform is required to increase its use. Yet, these arguments are made primarily on anecdotes; the empirical evidence is scant. One foundational question is how many drugs are repositioned each year in Europe. This study develops a method to examine the number authorised each year. The results show a marked increase in repositioning over the last 3 years, and that the number per year is comparable, though slightly fewer than, the number of new compounds, indicating modest to higher‐than‐expected activity. This study considers what the results mean for four suggested reform options, including the EU Commission's recent proposal. We conclude that the reforms may not achieve their goals or that further evidence is required before we can know whether they will be effective. Lastly, this paper explains how the method and data in this study could serve as a benchmark for evaluating the success of future reforms.
- 26 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (753) , eadl0998
New government drug repurposing programs: Opportunities and uncertainties
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.
- 26 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (753) , eadl0998
New government drug repurposing programs: Opportunities and uncertainties
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, partially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europe have created seven drug development programs that aim to overcome these challenges using a variety of different strategies.
- Open Access
- 12 September 2022
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 53 (9) , 1287-1322
Repositioning Generic Drugs: Empirical Findings and Policy Implications
- 12 September 2022
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 53 (9) , 1287-1322
Open AccessRepositioning Generic Drugs: Empirical Findings and Policy Implications
- 8 July 2022
- Published by Edward Elgar Publishing
- p. 19-42
Patent eligibility and precision medicine: emerging technologies, legal flux and empirical methods
The patent system is designed to be applied to new forms of technology. Yet, the uncertainties, ambiguities, and transformative potential inherent to an emerging field of technology present policymakers (including legislators, judges and authors of Patent Examination guidelines) with difficulties finding the right balance, sometimes leading to unpredictable legal flux. Precision medicine is a case in point, as seen from the shifts in patent eligibility laws in Europe (in the 1990s) and in the US (first in the 1980s and then in the 2010s). Empirical analysis is a useful tool for helping to steer the course through the confusion entailed by tumultuous legal change, and can help mitigate some of its more pernicious aspects.
- 8 July 2022
- Published by Edward Elgar Publishing
- p. 19-42
Patent eligibility and precision medicine: emerging technologies, legal flux and empirical methods
The patent system is designed to be applied to new forms of technology. Yet, the uncertainties, ambiguities, and transformative potential inherent to an emerging field of technology present policymakers (including legislators, judges and authors of Patent Examination guidelines) with difficulties finding the right balance, sometimes leading to unpredictable legal flux. Precision medicine is a case in point, as seen from the shifts in patent eligibility laws in Europe (in the 1990s) and in the US (first in the 1980s and then in the 2010s). Empirical analysis is a useful tool for helping to steer the course through the confusion entailed by tumultuous legal change, and can help mitigate some of its more pernicious aspects.
- 13 April 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (4) , 465-471
European patent protection for medical uses of known products and drug repurposing
- 13 April 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (4) , 465-471
European patent protection for medical uses of known products and drug repurposing
- 9 November 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1336-1343
Mapping the European patent landscape for medical uses of known products
- 9 November 2021
- Published by Springer Nature in Nature Biotechnology
- Vol. 39 (11) , 1336-1343
Mapping the European patent landscape for medical uses of known products
- Open Access
- 20 July 2021
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 52 (7) , 825-851
Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity
EU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioning their drugs before and after the +1 came into effect. The results show that: (i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and (ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.
- 20 July 2021
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 52 (7) , 825-851
Open AccessHas the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity
EU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioning their drugs before and after the +1 came into effect. The results show that: (i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and (ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.
- 9 March 2020
- Published by Springer Nature in Nature Biotechnology
- Vol. 38 (3) , 279-283
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
- 9 March 2020
- Published by Springer Nature in Nature Biotechnology
- Vol. 38 (3) , 279-283
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?